IBDEI08R ; ; 06-AUG-2013
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;AUG 06, 2013
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,11623,1,4,0)
 ;;=4^280.9
 ;;^UTILITY(U,$J,358.3,11623,1,5,0)
 ;;=5^Iron Defic Anemia(Unspecified)
 ;;^UTILITY(U,$J,358.3,11623,2)
 ;;=^276946
 ;;^UTILITY(U,$J,358.3,11624,0)
 ;;=285.1^^77^667^73
 ;;^UTILITY(U,$J,358.3,11624,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11624,1,4,0)
 ;;=4^285.1
 ;;^UTILITY(U,$J,358.3,11624,1,5,0)
 ;;=5^Iron Defic Anemia d/t Acute Blood Loss
 ;;^UTILITY(U,$J,358.3,11624,2)
 ;;=^267986
 ;;^UTILITY(U,$J,358.3,11625,0)
 ;;=280.0^^77^667^72
 ;;^UTILITY(U,$J,358.3,11625,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11625,1,4,0)
 ;;=4^280.0
 ;;^UTILITY(U,$J,358.3,11625,1,5,0)
 ;;=5^Iron Defic Anemia Due To Chronic Blood Loss
 ;;^UTILITY(U,$J,358.3,11625,2)
 ;;=^267971
 ;;^UTILITY(U,$J,358.3,11626,0)
 ;;=281.9^^77^667^92
 ;;^UTILITY(U,$J,358.3,11626,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11626,1,4,0)
 ;;=4^281.9
 ;;^UTILITY(U,$J,358.3,11626,1,5,0)
 ;;=5^Nutritional Anemia
 ;;^UTILITY(U,$J,358.3,11626,2)
 ;;=^123801
 ;;^UTILITY(U,$J,358.3,11627,0)
 ;;=281.0^^77^667^93
 ;;^UTILITY(U,$J,358.3,11627,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11627,1,4,0)
 ;;=4^281.0
 ;;^UTILITY(U,$J,358.3,11627,1,5,0)
 ;;=5^Pernicious Anemia
 ;;^UTILITY(U,$J,358.3,11627,2)
 ;;=^7161
 ;;^UTILITY(U,$J,358.3,11628,0)
 ;;=282.60^^77^667^100
 ;;^UTILITY(U,$J,358.3,11628,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11628,1,4,0)
 ;;=4^282.60
 ;;^UTILITY(U,$J,358.3,11628,1,5,0)
 ;;=5^Sickle-Cell Anemia
 ;;^UTILITY(U,$J,358.3,11628,2)
 ;;=^7188
 ;;^UTILITY(U,$J,358.3,11629,0)
 ;;=282.62^^77^667^101
 ;;^UTILITY(U,$J,358.3,11629,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11629,1,4,0)
 ;;=4^282.62
 ;;^UTILITY(U,$J,358.3,11629,1,5,0)
 ;;=5^Sickle-Cell With Crisis
 ;;^UTILITY(U,$J,358.3,11629,2)
 ;;=^267982
 ;;^UTILITY(U,$J,358.3,11630,0)
 ;;=281.1^^77^667^110
 ;;^UTILITY(U,$J,358.3,11630,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11630,1,4,0)
 ;;=4^281.1
 ;;^UTILITY(U,$J,358.3,11630,1,5,0)
 ;;=5^Vit B12 Deficiency(Dietary)
 ;;^UTILITY(U,$J,358.3,11630,2)
 ;;=^267974
 ;;^UTILITY(U,$J,358.3,11631,0)
 ;;=286.7^^77^667^44
 ;;^UTILITY(U,$J,358.3,11631,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11631,1,4,0)
 ;;=4^286.7
 ;;^UTILITY(U,$J,358.3,11631,1,5,0)
 ;;=5^Coagulation Defect(Any),Acquired
 ;;^UTILITY(U,$J,358.3,11631,2)
 ;;=^2235
 ;;^UTILITY(U,$J,358.3,11632,0)
 ;;=289.9^^77^667^107
 ;;^UTILITY(U,$J,358.3,11632,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11632,1,4,0)
 ;;=4^289.9
 ;;^UTILITY(U,$J,358.3,11632,1,5,0)
 ;;=5^Thrombocytosis, Essential
 ;;^UTILITY(U,$J,358.3,11632,2)
 ;;=^55344
 ;;^UTILITY(U,$J,358.3,11633,0)
 ;;=451.9^^77^667^108
 ;;^UTILITY(U,$J,358.3,11633,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11633,1,4,0)
 ;;=4^451.9
 ;;^UTILITY(U,$J,358.3,11633,1,5,0)
 ;;=5^Thrombophlebitis 
 ;;^UTILITY(U,$J,358.3,11633,2)
 ;;=^93357
 ;;^UTILITY(U,$J,358.3,11634,0)
 ;;=446.6^^77^667^109
 ;;^UTILITY(U,$J,358.3,11634,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11634,1,4,0)
 ;;=4^446.6
 ;;^UTILITY(U,$J,358.3,11634,1,5,0)
 ;;=5^Thrombotic Thrombocytopenic Purpura(Ttp)
 ;;^UTILITY(U,$J,358.3,11634,2)
 ;;=^119061
 ;;^UTILITY(U,$J,358.3,11635,0)
 ;;=286.4^^77^667^111
 ;;^UTILITY(U,$J,358.3,11635,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11635,1,4,0)
 ;;=4^286.4
 ;;^UTILITY(U,$J,358.3,11635,1,5,0)
 ;;=5^Von Willebrand'S Disease
 ;;^UTILITY(U,$J,358.3,11635,2)
 ;;=^127267
 ;;^UTILITY(U,$J,358.3,11636,0)
 ;;=204.00^^77^667^2
 ;;^UTILITY(U,$J,358.3,11636,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11636,1,4,0)
 ;;=4^204.00
 ;;^UTILITY(U,$J,358.3,11636,1,5,0)
 ;;=5^ALL w/o Remission
 ;;^UTILITY(U,$J,358.3,11636,2)
 ;;=^267521
 ;;^UTILITY(U,$J,358.3,11637,0)
 ;;=204.01^^77^667^1
 ;;^UTILITY(U,$J,358.3,11637,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11637,1,4,0)
 ;;=4^204.01
 ;;^UTILITY(U,$J,358.3,11637,1,5,0)
 ;;=5^ALL in Remission
 ;;^UTILITY(U,$J,358.3,11637,2)
 ;;=^267522
 ;;^UTILITY(U,$J,358.3,11638,0)
 ;;=204.10^^77^667^20
 ;;^UTILITY(U,$J,358.3,11638,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11638,1,4,0)
 ;;=4^204.10
 ;;^UTILITY(U,$J,358.3,11638,1,5,0)
 ;;=5^CLL w/o Remission
 ;;^UTILITY(U,$J,358.3,11638,2)
 ;;=^267523
 ;;^UTILITY(U,$J,358.3,11639,0)
 ;;=204.11^^77^667^19
 ;;^UTILITY(U,$J,358.3,11639,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11639,1,4,0)
 ;;=4^204.11
 ;;^UTILITY(U,$J,358.3,11639,1,5,0)
 ;;=5^CLL in Remission
 ;;^UTILITY(U,$J,358.3,11639,2)
 ;;=^267524
 ;;^UTILITY(U,$J,358.3,11640,0)
 ;;=201.90^^77^667^71
 ;;^UTILITY(U,$J,358.3,11640,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11640,1,4,0)
 ;;=4^201.90
 ;;^UTILITY(U,$J,358.3,11640,1,5,0)
 ;;=5^Hodgkin'S Lymphoma, Unpsec Type & Site
 ;;^UTILITY(U,$J,358.3,11640,2)
 ;;=^267430
 ;;^UTILITY(U,$J,358.3,11641,0)
 ;;=785.6^^77^667^77
 ;;^UTILITY(U,$J,358.3,11641,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11641,1,4,0)
 ;;=4^785.6
 ;;^UTILITY(U,$J,358.3,11641,1,5,0)
 ;;=5^Lymphadenopathy
 ;;^UTILITY(U,$J,358.3,11641,2)
 ;;=^72368
 ;;^UTILITY(U,$J,358.3,11642,0)
 ;;=200.20^^77^667^78
 ;;^UTILITY(U,$J,358.3,11642,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11642,1,4,0)
 ;;=4^200.20
 ;;^UTILITY(U,$J,358.3,11642,1,5,0)
 ;;=5^Lymphoma, Burkitt'S, Unspecified Sites
 ;;^UTILITY(U,$J,358.3,11642,2)
 ;;=^17529
 ;;^UTILITY(U,$J,358.3,11643,0)
 ;;=202.00^^77^667^80
 ;;^UTILITY(U,$J,358.3,11643,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11643,1,4,0)
 ;;=4^202.00
 ;;^UTILITY(U,$J,358.3,11643,1,5,0)
 ;;=5^Lymphoma, Low-Grade, Unspec Site
 ;;^UTILITY(U,$J,358.3,11643,2)
 ;;=^72606
 ;;^UTILITY(U,$J,358.3,11644,0)
 ;;=200.10^^77^667^79
 ;;^UTILITY(U,$J,358.3,11644,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11644,1,4,0)
 ;;=4^200.10
 ;;^UTILITY(U,$J,358.3,11644,1,5,0)
 ;;=5^Lymphoma, Int Or High Grade, Unspec Site
 ;;^UTILITY(U,$J,358.3,11644,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,11645,0)
 ;;=273.3^^77^667^81
 ;;^UTILITY(U,$J,358.3,11645,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11645,1,4,0)
 ;;=4^273.3
 ;;^UTILITY(U,$J,358.3,11645,1,5,0)
 ;;=5^Macroglobulinemia
 ;;^UTILITY(U,$J,358.3,11645,2)
 ;;=^73013
 ;;^UTILITY(U,$J,358.3,11646,0)
 ;;=203.00^^77^667^90
 ;;^UTILITY(U,$J,358.3,11646,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11646,1,4,0)
 ;;=4^203.00
 ;;^UTILITY(U,$J,358.3,11646,1,5,0)
 ;;=5^Multiple Myeloma W/O Rem
 ;;^UTILITY(U,$J,358.3,11646,2)
 ;;=^267514
 ;;^UTILITY(U,$J,358.3,11647,0)
 ;;=203.01^^77^667^89
 ;;^UTILITY(U,$J,358.3,11647,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11647,1,4,0)
 ;;=4^203.01
 ;;^UTILITY(U,$J,358.3,11647,1,5,0)
 ;;=5^Multiple Myeloma In Remission
 ;;^UTILITY(U,$J,358.3,11647,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,11648,0)
 ;;=238.6^^77^667^94
 ;;^UTILITY(U,$J,358.3,11648,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11648,1,4,0)
 ;;=4^238.6
 ;;^UTILITY(U,$J,358.3,11648,1,5,0)
 ;;=5^Plasmacytoma Nos
 ;;^UTILITY(U,$J,358.3,11648,2)
 ;;=^81973
 ;;^UTILITY(U,$J,358.3,11649,0)
 ;;=205.00^^77^667^4
 ;;^UTILITY(U,$J,358.3,11649,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11649,1,4,0)
 ;;=4^205.00
 ;;^UTILITY(U,$J,358.3,11649,1,5,0)
 ;;=5^AML w/o Remission
 ;;^UTILITY(U,$J,358.3,11649,2)
 ;;=^267531
 ;;^UTILITY(U,$J,358.3,11650,0)
 ;;=205.01^^77^667^3
 ;;^UTILITY(U,$J,358.3,11650,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11650,1,4,0)
 ;;=4^205.01
 ;;^UTILITY(U,$J,358.3,11650,1,5,0)
 ;;=5^AML in Remission
 ;;^UTILITY(U,$J,358.3,11650,2)
 ;;=^267532
 ;;^UTILITY(U,$J,358.3,11651,0)
 ;;=205.10^^77^667^22
 ;;^UTILITY(U,$J,358.3,11651,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11651,1,4,0)
 ;;=4^205.10
 ;;^UTILITY(U,$J,358.3,11651,1,5,0)
 ;;=5^CML w/o Remission
 ;;^UTILITY(U,$J,358.3,11651,2)
 ;;=^267533
 ;;^UTILITY(U,$J,358.3,11652,0)
 ;;=205.11^^77^667^21
 ;;^UTILITY(U,$J,358.3,11652,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11652,1,4,0)
 ;;=4^205.11
 ;;^UTILITY(U,$J,358.3,11652,1,5,0)
 ;;=5^CML in Remission
 ;;^UTILITY(U,$J,358.3,11652,2)
 ;;=^267534
 ;;^UTILITY(U,$J,358.3,11653,0)
 ;;=289.0^^77^667^45
 ;;^UTILITY(U,$J,358.3,11653,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11653,1,4,0)
 ;;=4^289.0
 ;;^UTILITY(U,$J,358.3,11653,1,5,0)
 ;;=5^Erthryocytosis, Secondary
 ;;^UTILITY(U,$J,358.3,11653,2)
 ;;=^186856
 ;;^UTILITY(U,$J,358.3,11654,0)
 ;;=238.4^^77^667^95
 ;;^UTILITY(U,$J,358.3,11654,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11654,1,4,0)
 ;;=4^238.4
 ;;^UTILITY(U,$J,358.3,11654,1,5,0)
 ;;=5^Polycythemia Vera
 ;;^UTILITY(U,$J,358.3,11654,2)
 ;;=^96105
 ;;^UTILITY(U,$J,358.3,11655,0)
 ;;=V58.61^^77^667^112
 ;;^UTILITY(U,$J,358.3,11655,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11655,1,4,0)
 ;;=4^V58.61
 ;;^UTILITY(U,$J,358.3,11655,1,5,0)
 ;;=5^Warfarin/Coumadin Use
 ;;^UTILITY(U,$J,358.3,11655,2)
 ;;=Warfarin/Coumadin Use^303459
 ;;^UTILITY(U,$J,358.3,11656,0)
 ;;=282.49^^77^667^105
 ;;^UTILITY(U,$J,358.3,11656,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11656,1,4,0)
 ;;=4^282.49
 ;;^UTILITY(U,$J,358.3,11656,1,5,0)
 ;;=5^Thalassemia Nec
 ;;^UTILITY(U,$J,358.3,11656,2)
 ;;=^329910
 ;;^UTILITY(U,$J,358.3,11657,0)
 ;;=289.89^^77^667^13
 ;;^UTILITY(U,$J,358.3,11657,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11657,1,4,0)
 ;;=4^289.89
 ;;^UTILITY(U,$J,358.3,11657,1,5,0)
 ;;=5^Blood Diseases Nec
 ;;^UTILITY(U,$J,358.3,11657,2)
 ;;=^329887
 ;;^UTILITY(U,$J,358.3,11658,0)
 ;;=238.79^^77^667^76
 ;;^UTILITY(U,$J,358.3,11658,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11658,1,4,0)
 ;;=4^238.79
 ;;^UTILITY(U,$J,358.3,11658,1,5,0)
 ;;=5^LYMPH/HEMATPOITC TIS NEC
 ;;^UTILITY(U,$J,358.3,11658,2)
 ;;=^334033
 ;;^UTILITY(U,$J,358.3,11659,0)
 ;;=287.30^^77^667^96
 ;;^UTILITY(U,$J,358.3,11659,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11659,1,4,0)
 ;;=4^287.30
 ;;^UTILITY(U,$J,358.3,11659,1,5,0)
 ;;=5^Primary Thrombocytopenia
 ;;^UTILITY(U,$J,358.3,11659,2)
 ;;=^332841
 ;;^UTILITY(U,$J,358.3,11660,0)
 ;;=288.09^^77^667^6
 ;;^UTILITY(U,$J,358.3,11660,1,0)
 ;;=^358.31IA^5^2
